- Home
- NHIV vs ARCT Comparison
NHIV vs ARCT Comparison
Compare NHIV & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NHIV | ARCT |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.8M | 293.9M |
| IPO Year | 2026 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NHIV | ARCT |
|---|---|---|
| Price | $9.95 | $11.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 60.5K | ★ 605.3K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.95 | $5.50 |
| 52 Week High | $10.16 | $17.96 |
Technical Indicators
Market Signals| Indicator | NHIV | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 47.57 |
| Support Level | N/A | $6.53 |
| Resistance Level | $10.16 | $17.85 |
| Average True Range (ATR) | 0.01 | 0.87 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 0.00 | 65.00 |
Price Performance
Historical ComparisonAbout NHIV NewHold Investment Corp IV Class A Ordinary Shares
NewHold Investment Corp IV is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.